Fulcrum Therapeutics, Inc. (FULC) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
FULC EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
FULC Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | 20.8% | -27.4% | -12.2% |
| 2023 | 100.0% | -3945.2% | -3470.1% |
| 2022 | -1110.7% | -1774.9% | -1732.4% |
| 2021 | -263.7% | -423.0% | -421.9% |
Download Data
Export FULC earnings history in CSV or JSON format
Free sign-in required to download data
Fulcrum Therapeutics, Inc. (FULC) Earnings Overview
As of May 8, 2026, Fulcrum Therapeutics, Inc. (FULC) reported trailing twelve-month net income of -$76M, reflecting -637.5% year-over-year growth. The company earned $-1.00 per diluted share over the past four quarters.
Looking at the long-term picture, FULC's historical earnings data spans multiple years. The company achieved its highest annual net income of -$10M in fiscal 2024.
Fulcrum Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARWR (-$301M net income, -0.2% margin), SRPT ($65M net income, -32.5% margin), FOLD (-$27M net income, -4.3% margin), FULC has comparable earnings metrics. Compare FULC vs ARWR →
FULC Earnings vs Peers
Earnings metrics vs comparable public companies
FULC Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$75M | -670.0% | -$85M | $-1.18 | - | - |
| 2024 | -$10M | +90.0% | -$22M | $-0.16 | -12.2% | -27.4% |
| 2023 | -$97M | +11.4% | -$111M | $-1.59 | -3470.1% | -3945.2% |
| 2022 | -$110M | -35.9% | -$113M | $-2.35 | -1732.4% | -1774.9% |
| 2021 | -$81M | -14.2% | -$81M | $-2.22 | -421.9% | -423.0% |
| 2020 | -$71M | +14.3% | -$72M | $-2.70 | -802.7% | -811.6% |
| 2019 | -$83M | -153.7% | -$59M | $-3.49 | - | - |
| 2018 | -$33M | -41.9% | -$33M | $-1.92 | - | - |
| 2017 | -$23M | - | -$23M | $-1.36 | - | - |
See FULC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FULC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FULC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFULC — Frequently Asked Questions
Quick answers to the most common questions about buying FULC stock.
Is FULC growing earnings?
FULC EPS fell to $-1.00, with earnings declining -637.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-76M.
What are FULC's profit margins?
Fulcrum Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are FULC's earnings?
FULC earnings data spans 2017-2025. The declining earnings trend is -637.5% YoY. Historical data enables comparison across business cycles.